信達生物(1801.HK)漲近7% 獲高盛看高至60.35港元
格隆匯9月9日丨信達生物盤初拉昇漲近7%報29港元。高盛曾在8月底發佈研報稱,信達生物上半年業績大致符合預期,將其目標價由60.3港元微升至60.35港元,評級買入。野村也將其目標價由45.38港元上調至45.44港元。另外,德銀在最新的研報中給予其41港元的目標。德銀稱,公司雖然上半年受疫情和銷售團隊重組影響收入增長平平,但銷售團隊成功重組,對集團在擠擁的市場空間中保持競爭力至關重要,預計集團第三季業績中會看到部分成功的早期跡象。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.